Fulcrum Therapeutics, Inc.
US ˙ NasdaqGM ˙ US3596161097

SecurityFULC / Fulcrum Therapeutics, Inc.
InstitutionFranklin Resources Inc
Latest Disclosed Ownership54,666 shares
Latest Disclosed Value $ 419,288
Franklin Resources Inc reports 23.54% increase in ownership of FULC / Fulcrum Therapeutics, Inc.

On May 13, 2026 - Franklin Resources Inc filed a 13F-HR form disclosing ownership of 54,666 shares of Fulcrum Therapeutics, Inc. (US:FULC) valued at $419,288 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 44,249 shares of Fulcrum Therapeutics, Inc.. This represents a change in shares of 23.54% during the quarter. The current value of the position is $184,224 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F FULCRUM THERAPEUTICS COM 359616109 54,666 10,417 23.54 419 -16.20 0.0000
2026-02-11 2025-12-31 13F FULCRUM THERAPEUTICS COM 359616109 44,249 -15,773 -26.28 500 -9.42 0.0001
2025-11-13 2025-09-30 13F FULCRUM THERAPEUTICS COM 359616109 60,022 0 0.00 552 33.98 0.0001
2025-08-12 2025-06-30 13F FULCRUM THERAPEUTICS COM 359616109 60,022 35,201 141.82 413 480.28 0.0001
2025-05-13 2025-03-31 13F FULCRUM THERAPEUTICS COM 359616109 24,821 0 0.00 71 -38.79 0.0000
2025-02-12 2024-12-31 13F FULCRUM THERAPEUTICS COM 359616109 24,821 0 0.00 117 31.82 0.0000
2024-11-27 2024-09-30 13F/A-1 FULCRUM THERAPEUTICS COM 359616109 24,821 0 0.00 89 -42.48 0.0000
2024-11-12 2024-09-30 13F FULCRUM THERAPEUTICS COM 359616109 24,821 0 89 0.0000
2024-08-14 2024-06-30 13F FULCRUM THERAPEUTICS COM 359616109 24,821 0 0.00 154 -34.62 0.0000
2024-05-13 2024-03-31 13F FULCRUM THERAPEUTICS COM 359616109 24,821 0 0.00 234 40.12 0.0001
2024-02-09 2023-12-31 13F FULCRUM THERAPEUTICS COM 359616109 24,821 -3,535 -12.47 168 33.60 0.0001
2023-11-13 2023-09-30 13F FULCRUM THERAPEUTICS COM 359616109 28,356 0 0.00 126 34.41 0.0001
2023-08-11 2023-06-30 13F FULCRUM THERAPEUTICS COM 359616109 28,356 28,356 94 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.